Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
HOOKIPA Pharma Inc
HOOK | US
1.13
USD-0.01
-0.88%
HOOK | US
About HOOKIPA Pharma Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
10/04/2026
Close
1.13
Open
1.12
High
1.14
Low
1.12
HOOKIPA Pharma Inc. a clinical stage biopharmaceutical company develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101 which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic colorectal and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment cure diagnosis or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York New York.
View LessHOOK | US
Risk
43.5
Sharpe
0.67
Luna's Score
48/100
Recommendation
Hold
Luna says (HOOK | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
High Short-term Volatility
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
44.0%1 month
43.5%3 months
37.5%6 months
33.8%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.47
Debt to equity
0.06
Debt to assets
0.04
Ent. to EBITDA
0.46
Ent. to rev.
1.91
PEG
-
Other Fundamentals
EBITDA
-47.71M
MarketCap
11.18M
MarketCap(USD)
11.18M
Div. yield
-
Op. margin
-1.74K
Erngs. growth
-
Rev. growth
-51.80
Ret. on equity
-48.99
Short ratio
1.38
Short perc.
0.45
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.14
Range1M
0.14
Range3M
0.26
Volumes: Market Activity
Rel. volume
0.71
Price X volume
6.89K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.46 | - | Par |
| Ent. to Revenue | 1.91 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.47 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 37.46 | - | Lower Risk |
| Debt to Equity | 0.06 | -1.23 | Expensive |
| Debt to Assets | 0.04 | 0.25 | Cheaper |
| Market Cap | 11.18M | - | Emerging |
